በVirginia ለየክሮን በሽታ የሚደረጉ ክሊኒካዊ ጥናቶች
ለየክሮን በሽታ የሚደረጉ 15 ጥናቶች በVirginia ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በVirginia ውስጥ ያሉ ከተሞች
Official study text (English)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- University of Virginia Health System ( Site 0291), Charlottesville
ተሳታዮችን በመፈለግ ላይደረጃ 3
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT06651281A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Richmond VA Medical Center ( Site 5021), Richmond
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ16 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Emeritas Research Group /ID# 284388, Lansdowne Town Center
- GI Alliance - Richmond /ID# 284244, Richmond
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Gastroenterology Consultants of Southwest Virginia., Roanoke
ተሳታዮችን በመፈለግ ላይደረጃ 4
እድሜ ከ18 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT06581328A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Associates of Tidewater, Chesapeake
- Blue Ridge Medical Research, Lynchburg
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT07196722Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- VCU Massey Comprehensive Cancer Center, Richmond
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ሴፕቴ 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Blue Ridge Medical Research-Site Number: 8400020, Lynchburg
- Clinical Research Partners-Site Number: 8400080, Richmond
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ16 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ23 ሴፕቴ 2026 · NCT07184931A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Gastroenterology Associates of Central Virginia, Lynchburg
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 85 · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT06226883A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Pediatric Specialists of Virginia, Fairfax
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ2 እስከ 19 · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT04844606A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Carilion Children's Tanglewood Center, Roanoke
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 2 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ7 ሜይ 2026 · NCT05442567Precise Infliximab Exposure and Pharmacodynamic Control
- Children's Specialty Group, Norfolk
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
እድሜ ከ6 እስከ 22 · ሁሉም ጾታዎች · የተሻሻለው በ5 ሜይ 2026 · NCT05660746A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Carilion Children's Tanglewood Center, Roanoke
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ2 እስከ 17 · ሁሉም ጾታዎች · የተሻሻለው በ5 ሜይ 2026 · NCT04779320Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Richmond VA Medical Center, Richmond
- Gastroenterology Consultants of Southwest Virginia., Roanoke
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ27 ኤፕሪ 2026 · NCT06456593Ketogenic and Carnivore (Lion) Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis
- Resilient Roots: Functional Medicine, Charlottesville
ተሳታዮችን በመፈለግ ላይ
እድሜ ከ18 እስከ 64 · ሁሉም ጾታዎች · የተሻሻለው በ16 ኤፕሪ 2026 · NCT07524244A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400027, Richmond
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ27 ማርች 2026 · NCT06958536ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።